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Bone is the second most manipulated tissue after blood. Adipose-derived stem cells (ASCs) may become a convenient source of
MSC for bone regenerative protocols. Surprisingly, little is known about the most significant biomolecules these cells produce
and release after being osteoinduced. Therefore, the present study aimed at dosing 13 candidates chosen among the most
representative cytokines, chemokines, and growth factors within the conditioned media of osteodifferentiated and
undifferentiated ASCs. Two acknowledged osteoblastic cell models, that is, MG-63 and SaOs-2 cells, were compared. Notably,
IL-6, IL-8, MCP-1, and VEGF were highly produced and detectable in ASCs. In addition, while IL-6 and IL-8 seemed to be
significantly induced by the osteogenic medium, no such effect was seen for MCP-1 and VEGF. Overall SaOS-2 had a poor
expression profile, which may be consistent with the more differentiated phenotype of SaOs-2 compared to ASCs and MG-63.
Instead, in maintaining medium, MG-63 displayed a very rich production of IL-12, MCP-1, IP-10, and VEGF, which were
significantly reduced in osteogenic conditions, with the only exception of MCP-1. The high expression of MCP-1 and VEGF,
even after the osteogenic commitment, may support the usage of ASCs in bone regenerative protocols by recruiting both
osteoblasts and osteoclasts of the host.
1. Introduction
Unlike the majority of adult tissues, bone is capable to self-
repair without forming scars, as most fractures demonstrate
by healing spontaneously [1] or through mild surgery. Not-
withstanding this inherent regenerative capacity of bone, at
least one tenth of themore than6.2million fractures [2] occur-
ring yearly suffer from impaired healing. In addition, inborn
malformations, alveolar resorption, and critical-size bone
defects resulting from severe trauma or malignant tumor
resection [3] make bone the second most transplanted tissue
after blood [4]. Treatments include grafting with both autoge-
nous andallogenic bone,which arenotwithout limitations [5].
Autogenous bone is widely considered the gold standard
of bone grafting materials. Nevertheless, there are still some
limits to the use of autogenous bone due to the donor site
morbidity, the difficulty in obtaining it, and the prolonged
healing time [6, 7]. Recently, autologous bone has been used
for the regeneration of bony structures and defects [8]. How-
ever, autologous bone administration has been highly associ-
ated with the risk of disease transmission and immune
reaction [9]. Furthermore, synthetic bone grafting materials
have been produced to mimic the bone structure and to pro-
moteosteoconduction.However, fabricating andmanufactur-
ing these graft materials preclude their extensive application
due to the involved primary expenses [7, 10].
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One of the major goals of tissue engineering [11] is to
overcome the pitfalls traditional techniques face when
applied to treat large bone defects [12]. Among the three
key components of each regenerative protocol, besides
scaffolds and signaling molecules, cells play a paramount
role. To this end, primary multipotent stem cells, along
with several immortalized cell lines, have been widely used
for cytocompatibility testing and osteogenic potential eval-
uation of biomaterials in regenerative medicine [13]. How-
ever, the heterogeneity of these cells, too often simply
defined as osteoblasts or osteblastic precursors, should be
carefully considered.
Albeit easy to obtain and handle, tumor-derived cell lines
may present peculiar nonphysiological features [14]. For
instance, osteosarcoma cell lines (SaOs-2, MG-63, and U-2
OS) differ significantly from primary osteoblasts as for
immunocytochemical markers and matrix produced [15].
The most used human cell line SaOs-2 cells display a mature
osteoblast phenotype and form a calcified matrix resembling
woven bone [16]. SaOs-2 cells share with primary human
osteoblasts a similar expression profile of cytokines, growth
factors, and receptors for parathyroid hormone [17]. MG-
63 cell line represents an immature osteoblast phenotype.
Despite the inconsistencies about their mineralization capa-
bilities [14], MG-63 cells have been used in long-term studies
concerning cell behavior on biomaterials [18]. Notwithstand-
ing the abovementioned pitfalls, SaOs-2 and MG-63 cells are
the most studied osteoblasts.
On the other hand, primary stem cells are characterized
by higher variability and are usually available in smaller
amounts [19]. Although, mesenchymal stem cells deriving
from bone marrow are somehow archetypic [20, 21], more
recently, adipose-derived stem cells (ASCs) [22] have
emerged as a viable alternative source of mesenchymal cells.
As it has been exhaustively reviewed [23], ASCs are relatively
abundant and easy to access and may therefore become the
elective source of mesenchymal stem cells for bone regenera-
tive protocols. Surprisingly, however, little is known about
the most significant biomolecules osteo-committed cells pro-
duce and release. Therefore, the present study aimed at
dosing 13 candidates chosen among the most representative
cytokines, chemokines, and growth factors within the condi-
tioned media of osteodifferentiated and undifferentiated
ASCs. As a complimentary analysis, two acknowledged
“osteoblastic” cell models were compared, based on their
different maturation stage.
2. Materials and Methods
2.1. Cell Culture. ASCs were isolated from fat tissue obtained
from three different donors as described previously [22] and
maintained in Dulbecco’s minimum essential medium
enriched with sodium pyruvate and supplemented with
10% foetal bovine serum (FBS, Gibco Life Technologies),
100U/ml penicillin, 100μg/ml streptomycin, and 250 ng/ml
amphotericin B. The nonadherent cell population was
removed after 48 h, and the adherent cell layer was washed
twice with fresh medium; cells were then continuously cul-
tured since their harvest until sixth passage. SaOs-2 (ATCC
number: HTB-85) and MG-63 (ATCC number: CRL-1427)
cells were, respectively, cultured in McCoy’5A (Gibco, Life
Technologies) with 15% FBS (Benchmark, Gemini Bio-Prod-
ucts) and in Dulbecco’s modified eagle’s medium (DMEM,
Gibco, Life Technologies) with 10% FBS. Both media were
supplemented with 1% penicillin-streptomycin (MD Bio-
medicals, Thermo Fisher Scientific). Cells were always pas-
saged at subconfluency to prevent contact inhibition and
were kept under a humidified atmosphere of 5% CO2 in
air, 37°C.
2.2. Detection of Interleukins, Chemokines, and Growth
Factors Using Bio-Plex System. To analyze the profile of the
biomolecules, cells were seeded in 96-well plates (103 cells/
well) in their own maintaining medium for 1 day. After-
wards, cells were incubated in RPMI in the presence of 2%
FBS and 2% FBS+osteogenic factors (50μM ascorbic acid,
10mM beta glycerophosphate, and 100nM dexamethasone)
either for 7 (T1) and 14 (T2) in the case of SaOs-2 or for 21
(T1) and 28 (T2) days in the case of MG-63 and ASCs. At
the day of harvest, media were removed, cells washed twice
in PBS, and fresh starving medium (RPMI 0.5% bovine
serum albumin) was incubated for 2 hours. Conditioned
media thus obtained were characterized, without adding
any activation substances, by measuring the concentration
of the following specific biomolecules: interleukin-2 (IL-2),
interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10
(IL-10), interleukin-12 (IL-12), granulocyte-colony stimulat-
ing factor (G-CSF), interferon-gamma (INF-γ), tumor
necrosis factor-α (TNF-α), monocyte chemoattractant
protein-1 (MCP-1) (CCL-2), CXCL10 chemokine (IP-10),
platelet-derived growth factor (PDGF), basic-fibroblastic
growth factor (bFGF), and vascular endothelial growth factor
(VEGF). The flexible Bio-Plex system (Bio-Rad Laboratories,
Hercules, CA, USA) was employed as previously described
[24]. All samples were analyzed following the manufacturer’s
protocol. At least two independent repetitions in duplicate
were made per sample. Concentrations of the analytes were
expressed in pg/ml. A standard curve ranging on average
from 0.15 pg/ml to 3700 pg/ml (High Photomultiplier Tube
Setting—PMT setting) was prepared and then fitted by Bio-
Plex Manager software.
2.3. In Vitro Osteogenic Differentiation Tests. In vitro osteo-
genic differentiation was performed at the same conditions
described above to run a series of assays aiming at revealing
established bone markers, as described elsewhere [25, 26].
2.3.1. Alkaline Phosphatase (ALP) Activity Assay. Alkaline
phosphatase (ALP) activity was determined using a colori-
metric end point assay [27, 28], which measures the conver-
sion of the colorless substrate p-nitrophenol phosphate
(PNPP) by the enzyme ALP to the yellow product p-
nitrophenol. To measure ALP activity, cells were lysed with
0.05% Triton X-100 and incubated with the reagent solution
containing phosphatase substrate (Sigma-Aldrich, Milan,
Italy) at 37°C for 15min. The rate of color change corre-
sponds to the amount of enzyme present in solution. Optical
density was measured at a wavelength of 405nm (reference
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620nm). Samples were compared against the calibration
curve of p-nitrophenol standards. The final alkaline phos-
phatase concentration was adjusted per total protein content,
to avoid biases due to the cell number. Therefore, part of the
cell lysates obtained for ALP quantification was incubated
with BCA™ (Thermo Fisher Scientific, Waltham, MA,
USA) protein assay, following to the manufacturer’s instruc-
tions. Optical density was measured at a wavelength of
570nm, and results were adjusted to a calibration curve made
by known number of cells. ALP values were determined and
normalized on whole protein content at day 3 in SaOs-2 and
at day 7 in MG-63 and ASCs.
2.3.2. Calcium Content Assay. Cell calcium content was
determined at day 14 for SaOs-2 and at day 21 for MG-63
and ASCs by Calcium colorimetric assay kit (BioVision
Research Products, Mountain View, CA, USA), according
to the manufacturer’s protocol. The OD was measured at
575nm within 20 minutes since preparation. A calibration
curve was always made.
2.3.3. Collagen and Calcium Staining. At the established time
points, cells grown in six-plate wells were washed once with
PBS and fixed with 4% paraformaldehyde for 10min at room
temperature. The solution was removed and cells were
washed with PBS. To stain collagen, Sirius Red dye (Direct
Red 80, Sigma-Aldrich) dissolved (1mg/ml) in a saturated
aqueous solution of picric acid (Sigma-Aldrich), was added
to the fixed cell cultures. After kept under mild shaking for
2 hours, samples were quickly rinsed in acid water (0.5%
acetic acid in pure water) and then abundantly washed with
distilled water. Calcium salts were stained after von Kossa
following published protocols [15]. For both picro-Sirius
Red and von Kossa stains, the cultures were observed under
light microscopy and representative pictures captured by an
Olympus camera.
2.4. Statistical Analysis. Data were analysed by GraphPad
Prism6 (GraphPad Software, Inc., La Jolla, CA, USA). Each
experiment was repeated at least three times. Statistical
analysis was performed by using the nonparametric test
Wilcoxon–Mann–Whitney test. A p value of <0.05 was
considered significant.
3. Results
3.1. Detection of Interleukins, Chemokines, and Growth
Factors. The concentrations of interleukin-2 (IL-2),
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Figure 1: Cytokine quantification. Cytokine levels of ASCs (a), MG-63 (b), and SaOS-2 (c) measured by Bio-Plex analysis are shown. Two
times (T1, T2) and two conditions (CM, OM) were considered for each cell line. For ASCs and MG-63, T1 = 21 days and T2 = 28 days; for
SaOs-2, T1 = 7 days and T2 = 14 days. CM= control medium (DMEM 2% FBS); OM=osteogenic medium (see Materials and Methods).
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Figure 2: Cytokine quantification 2.Data fromBio-Plex analysis are reported as different histograms for each cytokine. In particular, the quantification
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interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-
10), interleukin-12 (IL-12), granulocyte-colony stimulating
factor (G-CSF), interferon-gamma (INF-γ), tumor necrosis
factor-α (TNF-α), monocyte chemoattractant protein-1
(MCP-1) (CCL-2), CXCL10 chemokine (IP-10), platelet-
derived growth factor (PDGF), basic-fibroblastic growth fac-
tor (bFGF), and vascular endothelial growth factor (VEGF)
are reported in Figure 1 for ASCs, MG-63, and SaOs-2 cells
that were kept both under maintaining and differentiation
media.
Interestingly, there is a big difference in the expression
pattern of interleukins, chemokines, and growth factors
among different cells. ASCs produce a considerable level of
IL-6, IL-8, MCP-1, and VEGF without particular variations
between osteodifferentiated and control condition (with the
exception of IL-8). MG-63 shows high levels of expression
of IL-12, IP-10, MCP-1, and VEGF. Importantly, in osteodif-
ferentiating conditions, the expression of IL-12, IP-10, and
VEGF decreases. SaOs-2 cells show very low expression levels
of the considered molecules, except for the VEGF. Notably,
the osteodifferentiating medium inhibits the expression of
IL-12 and VEGF in SaOs-2, similarly to MG-63 cells. To fur-
ther highlight the differential expression of the considered
molecules among ASCs, MG-63, and SaOs-2 cells, a panel
showing the expression values for each biomolecule is
reported in Figure 2.
3.2. In Vitro Osteogenic Differentiation Tests. The osteogenic
potential of the cells has been assessed at the early stage by
quantifying ALP activity (Figure 3) and staining the collagen
matrix through Sirius Red (Figure 4). Interestingly, the osteo-
differentiating condition significantly increased the level of
ALP activity for each cell type. At later stages, the extracellu-
lar calcium content was determined colorimetrically
(Figure 5) and with the Von Kossa method (Figure 6). In
osteodifferentiating condition, a significant increase of
extracellular calcium content was found for each cell type.
Collectively, the differentiating condition appeared more
performing than the undifferentiated control, proving the
effectiveness of the osteogenic medium.
4. Discussion
In the present study, the differential expression of signaling
molecules among three different cell types under both osteo-
differentiating and control conditions is shown for the first
time. To achieve this, a highly sensitive method was used.
In particular, the cellular models considered in this work
are the ASC, the MG-63, and the SaOs-2 cells. Notably, the
ASCs represent a particular type of mesenchymal stem cells
of great potential applications in the context of bone regener-
ation. On the other hand, despite their ineligibility for clinical
use owing to their tumor derivation [29–31], MG-63 and
SaOs-2 cells were chosen to this study as they are a widely dif-
fused and accepted in vitro model, in the field of bone biology
[16, 17, 32–37]. This paper underlines also the differences in
the expression variations of signaling molecules during dif-
ferentiation among cells.
In 2001, Zuk et al. [22] described a putative population of
multipotent stem cells isolated through the enzymatic diges-
tion of the stromal vascular fraction of adipose tissue. Cul-
tured over time, these adherent cells display features of
multipotency; specifically, they tend to become relatively
homogenous trough passages and are capable to undergo dif-
ferentiation toward adipocytes, osteoblasts, and chondro-
cytes, under proper conditions [38]. Since this is true even
when expanded from a single clone, these cells have been
termed “adipose-derived stem cells” (ASCs) based on a con-
sensus reached by the Second Annual Meeting of the Interna-
tional Fat Applied Technology Society [39].
Notwithstanding the huge amount of research at the
in vitro and in vivo levels, the clinical usage of ASCs for bone
reconstruction has been limited. It is worth mentioning the
successful, although almost anecdotal, treatment of critical
bone defects in humans by the seeding of ASCs into poly
lactic-co-glycolic acid (PLGA) scaffolds [40] and beta-
tricalcium phosphate granules [41]. Bone restoration efforts
may profit from the combination with traditional tech-
niques such as grafts and ex vivo expansion under GMP
techniques [42]. Increasing interest has been focused on
the biomaterials used as carriers, as described, for instance,
by Mellor et al., who proposed stacked electrospun poly-
lactic acid nanofibrous scaffolds containing tricalcium
phosphate nanoparticles [43].
The actual efficacy of ASCs is, however, not solely
restricted to their differentiation capacity, but it owes also a
great deal to the delivery and localized secretion of signaling
molecules promoting, eventually, tissue recovery. Following
this research route, recent studies [43, 44] have explained
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Figure 3: ALP activity quantification. ALP activity was evaluated
recurring to a colorimetric assay. Values were normalized on
whole protein content at day 3 in SaOs-2 and at day 7 in MG-63
and ASCs. For each cell type, data were normalized on control
condition (CM) set as 1. OM condition significantly increase the
ALP activity in each cell type. CM= control medium (DMEM 2%
FBS); OM=osteogenic medium (see Materials and Methods).
Statistical analysis was performed by using the Wilcoxon–Mann–
Whitney test. A p value of <0.05 was considered significant.
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Figure 4: Collagen staining. Sirius Red dye staining was performed in order to show collagen deposition at day 3 in SaOs-2 and at day 7 in
MG-63 and ASCs. In OM condition, the staining is more intense for each cell type. CM= control medium (DMEM 2% FBS);
OM=osteogenic medium (see Materials and Methods). Images were taken at 100x magnification.
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the therapeutic effect of ASCs in ischemic models as a result
of the release of angiogenic factors such as HGF and VEGF.
Human ASCs were proven to secrete both factors constitu-
tively [45]. Kilroy et al. [46] reported that ASCs produce
angiogenic (HGF and VEGF), proinflammatory (IL-6, IL-8,
IL-11, LIF, and TNF alpha), and hematopoietic-supportive
cytokines (G-CSF, M-CSF, GM-CSF, and IL-7) following
exposure to common inductive factors including LPS.
Ribeiro and colleagues characterized the secretome of ASCs
with neurologic implications [47], while Succar and
coworkers profiled and compared different formulations for
cell therapy of osteoarthritis [48]. Nevertheless, to the
authors’ surprise, the scientific literature has lacked up to
now a comprehensive description of a significant range of
biomolecules secreted by ASCs subjected to osteogenic
differentiation, the great interest being more focused on the
intracellular dynamics.
Therefore, this study focused on the detection of a repre-
sentative panel of signaling molecules that ASCs, SaOs-2
cells, andMG-63 cells produce when cultured in either main-
taining or osteogenic medium. Each cell type behaved differ-
ently. It is noteworthy that IL-6, IL-8, MCP-1, and VEGF
were highly produced and detectable in ASCs even in the
absence of any stimulus. In addition, while IL-6 and IL-8
seemed to be significantly induced by the osteogenic
medium, no such effect was seen for MCP-1 and VEGF.
The multiplex immunological system here adopted called
Luminex® is capable to simultaneously detect and quantify
up to several hundreds of analytes across multiple samples,
reducing time, cost, and sample requirements in comparison
to ELISA assays [49]. The capture antibodies of Luminex rec-
ognise specific analytes and are attached to microbeads with
defined spectral address. The technique sensitivity thus
reaches concentrations even lower than 1pg/ml, which
explains, for instance, why we report on the presence of IL-
12 in ASCs contradicting Kilroy and colleagues’ outcomes
based on ELISA kits [46].
Overall SaOS-2 cells had a poor expression profile (only
IL-12 and VEGF resulted greater than 10 pg/ml), which
may be consistent with the more differentiated phenotype
of SaOs-2 cells compared to ASCs and MG-63, as thoroughly
reviewed elsewhere [14]. Instead, when kept in maintaining
medium, MG-63 cells displayed a very rich production of
IL-12, MCP-1, IP-10, and VEGF. This remarkable secretory
activity was inhibited by the osteogenic conditions, except
for MCP-1, a chemokine pivotal for macrophage activation
and thus bone remodeling. Notably, MCP-1, which is known
to be constitutively expressed in osteoblasts [50], was herein
enhanced in osteodifferentiated MG-63 cells.
The high level of IP-10 quantified in MG-63 cells may be
correlated to the tumor origin of the cell line [50, 51]. IP-10
was possibly produced in response to IFN-g, which was
detected only in MG-63 (as shown in Figures 1 and 2).
Compared to ASCs and SaOs-2, MG-63 produced also more
FGF-b, although the overall level is generally low. Consider-
ing these results, it could be interesting to investigate the
related TGF-b expression [52].
As noted above, contrary to MG-63 and SaOs-2 cells,
VEGF did not trend downward when ASCs were osteoin-
duced, even though the inhibitory effect of dexamethasone,
present in the osteogenic medium, is well known for endo-
thelial and tumoral cells [53, 54]. Along with the constitutive
high expression of MCP-1, the steady release of VEGF may
underpin the usage of ASCs for bone regenerative protocols,
where these biomolecules could contribute to recruit bone
cells within the host [55–58]. Very interestingly, Hu and
Olsen [55] studied bone repair in mice with a monocortical
defect within the tibial cortex. Osteoblast-derived VEGF
was proven to stimulate crosstalk between osteoblastic, endo-
thelial, and hematopoietic cells in a paracrine manner, while
directly affecting osteoblasts via autocrine mechanisms. The
role of MCP-1 was instead investigated as for the PTH-
induction during osteoclastogenesis by Li et al. [58], provid-
ing a rationale for increased osteoclast activity to initiate
greater bone remodeling.
On these premises, it will be of great interest to study
ASCs in a more physiologic context so as to provide more
reliable and predictive results. A possible approach might
consist in elucidating the behavior of ASCs in coculture sys-
tems, with endothelial cells that are known to be key players
in bone formation and regeneration [5].
5. Conclusion
Currently, the amount of proposals for the use of ASCs in tis-
sue repair and regeneration is impressive. The number of
clinical trials evaluating the efficacy and safety of ASCs in
the reconstruction and regeneration of tissues increases
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Figure 5: Calcium quantification. Cell calcium content was
determined kit recurring to a colorimetric assay. Evaluation was
performed at day 14 for SaOs-2 and at day 21 for MG-63 and ASCs.
For each cell type, data were normalized on control condition (CM)
set as 1. OM condition significantly increases the calcium content in
each cell type with a particularly high level in SaOs-2. CM= control
medium (DMEM 2% FBS); OM=osteogenic medium (see
Materials and Methods). Statistical analysis was performed by using
the Wilcoxon–Mann–Whitney test. A p value of <0.05 was
considered significant.
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significantly every year. According to the clinical trials
database (ClinicalTrials.gov database 2015), 122 studies are
currently using ASCs [59, 60].
In particular, positive results have been obtained using
autologous ASCs in clinical trials for craniofacial bone recon-
struction by producing new, mature, vital, and vascularized
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Figure 6: Calcium staining. Von Kossa staining was performed in order to show calcium deposition at day 14 for SaOs-2 and at day 21 for
MG-63 and ASCs. In OM condition, the staining is more intense for each cell type. CM= control medium (DMEM 2% FBS);
OM=osteogenic medium (see Materials and Methods). Images were taken at 100x magnification.
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bone [40–42, 61–63]. To date, bone regeneration is the most
promising field for clinical translation of experimental ASC
protocols [62]. This study supports, once more, the viability
of ASCs in bone tissue engineering based on the cytokines,
chemokines, and growth factors detected.
Disclosure
No involvement is to be reported at any stage of the study or
while preparing the paper.
Conflicts of Interest
The authors declare that there are no competing interests
regarding the publication of this paper.
Authors’ Contributions
F. Mussano and T. Genova equally contributed to this work.
Acknowledgments
This research was partly funded by the Piedmont Region
with the POLI D’INNOVAZIONE-III Annualità (research
project acronym: BIOBONE).
References
[1] T. A. Einhorn, “The science of fracture healing,” Journal of
Orthopaedic Trauma, vol. 19, no. 10, pp. S4–S6, 2005, August
2016, http://www.ncbi.nlm.nih.gov/pubmed/16479221.
[2] American Academy of Orthopaedic Surgeons,Musculoskeletal
Injuries Report: Incidence, Risk Factors and Prevention, AAOS,
Rosemont, IL, USA, 2000.
[3] M. D. McKee, “Management of segmental bony defects:
the role of osteoconductive orthobiologics,” The Journal
of the American Academy of Orthopaedic Surgeons,
vol. 14, no. 10, pp. S163–S167, 2006, August 2016, http://
www.ncbi.nlm.nih.gov/pubmed/17003191.
[4] P. Giannoudis, H. Dinopoulos, and E. Tsiridis, “Bone substi-
tutes: an update,” Injury, vol. 36, Supplement 3, pp. S20–S27,
2005.
[5] T. Genova, L. Munaron, S. Carossa, and F. Mussano,
“Overcoming physical constraints in bone engineering: “the
importance of being vascularized”,” Journal of Biomaterials
Applications, vol. 30, no. 7, pp. 940–951, 2016.
[6] M. E. Aichelmann-Reidy and R. A. Yukna, “Bone replace-
ment grafts. The bone substitutes,” Dental Clinics of North
America, vol. 42, no. 3, pp. 491–503, 1998, December
2016, http://www.ncbi.nlm.nih.gov/pubmed/9700451.
[7] G. Fernandes and S. Yang, “Application of platelet-rich plasma
with stem cells in bone and periodontal tissue engineering,”
Bone Research, vol. 4, article 16036, 2016.
[8] M. A. Brunsvold and J. T.Mellonig, “Bone grafts and periodon-
tal regeneration,” Periodontology 2000, vol. 1, no. 1, pp. 80–91,
1993, December 2016, http://www.ncbi.nlm.nih.gov/pubmed/
8401863.
[9] C. Delloye, “Bone grafts using tissue engineering,” Bulletin et
Mémoires de l'Académie Royale de Médecine de Belgique,
vol. 156, no. 7-9, pp. 418–425, 2001, December 2016, http://
www.ncbi.nlm.nih.gov/pubmed/11995186.
[10] W. Li, L. Xiao, and J. Hu, “The use of enamel matrix derivative
alone versus in combination with bone grafts to treat patients
with periodontal intrabony defects,” Journal of the American
Dental Association (1939), vol. 143, no. 9, pp. e46–e56, 2012.
[11] R. Langer and J. P. Vacanti, “Tissue engineering,” Science,
vol. 260, no. 5110, pp. 920–926, 1993.
[12] C. Szpalski, F. Sagebin, M. Barbaro, and S. M. Warren, “The
influence of environmental factors on bone tissue engineer-
ing,” Journal of Biomedical Materials Research. Part B, Applied
Biomaterials, vol. 101, no. 4, pp. 663–675, 2013.
[13] V. Kartsogiannis and K. W. Ng, “Cell lines and primary cell
cultures in the study of bone cell biology,” Molecular and
Cellular Endocrinology, vol. 228, no. 1, pp. 79–102, 2004.
[14] E. M. Czekanska, M. J. Stoddart, R. G. Richards, and J. S.
Hayes, “In search of an osteoblast cell model for in vitro
research,” European Cells and Materials, vol. 24, no. 4,
pp. 1–17, 2012, November 2015, http://www.ncbi.nlm.nih.
gov/pubmed/22777949.
[15] C. Pautke, M. Schieker, T. Tischer et al., “Characterization
of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in
comparison to human osteoblasts,” Anticancer Research,
vol. 24, no. 6, pp. 3743–3748, 2004, February 2015, http://
www.ncbi.nlm.nih.gov/pubmed/15736406.
[16] S. B. Rodan, Y. Imai, M. A. Thiede et al., “Characterization of a
human osteosarcoma cell line (Saos-2) with osteoblastic prop-
erties,” Cancer Research, vol. 47, no. 18, pp. 4961–4966, 1987,
January 2015, http://www.ncbi.nlm.nih.gov/pubmed/3040234.
[17] G. Bilbe, E. Roberts, M. A. Birch, and D. B. B. Evans, “PCR
phenotyping of cytokines, growth factors and their receptors
and bone matrix proteins in human osteoblast-like cell lines,”
Bone, vol. 19, no. 5, pp. 437–445, 1996.
[18] J. Lincks, B. D. Boyan, C. R. Blanchard et al., “Response of
MG63 osteoblast-like cells to titanium and titanium alloy is
dependent on surface roughness and composition,” Biomate-
rials, vol. 19, no. 23, pp. 2219–2232, 1998, January 2015,
http://www.ncbi.nlm.nih.gov/pubmed/9884063.
[19] C. Li, G. Wei, Q. Gu et al., “Donor age and cell passage affect
osteogenic ability of rat bone marrow mesenchymal stem
cells,” Cell Biochemistry and Biophysics, vol. 72, no. 2,
pp. 543–549, 2015.
[20] M. F. Pittenger, A. M. Mackay, S. C. Beck et al., “Multilineage
potential of adult human mesenchymal stem cells,” Science,
vol. 284, no. 5411, pp. 143–147, 1999, July 2014, http://www.
ncbi.nlm.nih.gov/pubmed/10102814.
[21] N. Jaiswal, S. E. Haynesworth, A. I. Caplan, and S. P. Bruder,
“Osteogenic differentiation of purified, culture-expanded
human mesenchymal stem cells in vitro,” Journal of Cellular
Biochemistry, vol. 64, no. 2, pp. 295–312, 1997.
[22] P. A. Zuk, M. Zhu, H. Mizuno et al., “Multilineage cells from
human adipose tissue: implications for cell-based therapies,”
Tissue Engineering, vol. 7, no. 2, pp. 211–228, 2001.
[23] U. D. Wankhade, M. Shen, R. Kolhe et al., “Advances in
adipose-derived stem cells isolation, characterization, and
application in regenerative tissue engineering,” Stem Cells
International, vol. 2016, Article ID 3206807, p. 9, 2016.
[24] F. Mussano, T. Genova, L. Munaron, S. Petrillo, F. Erovigni,
and S. Carossa, “Cytokine, chemokine, and growth factor
profile of platelet-rich plasma,” Platelets, vol. 27, no. 5,
pp. 467–471, 2016.
[25] F.Mussano, K. J. Lee, P. Zuk et al., “Differential effect of ionizing
radiation exposure onmultipotent and differentiation-restricted
9Stem Cells International
bone marrow mesenchymal stem cells,” Journal of Cellular
Biochemistry, vol. 111, no. 2, pp. 322–332, 2010.
[26] F. Mussano, A. Bartorelli Cusani, A. Brossa, S. Carossa, G.
Bussolati, and B. Bussolati, “Presence of osteoinductive factors
in bovine colostrum,” Bioscience, Biotechnology, and Biochem-
istry, vol. 78, no. 4, pp. 662–671, 2014.
[27] H. L. Holtorf, N. Datta, J. A. Jansen, and A. G. Mikos, “Scaffold
mesh size affects the osteoblastic differentiation of seeded
marrow stromal cells cultured in a flow perfusion bioreactor,”
Journal of Biomedical Materials Research. Part a, vol. 74, no. 2,
pp. 171–180, 2005.
[28] F. Mussano, T. Genova, P. Rivolo et al., “Role of surface
finishing on the in vitro biological properties of a silicon
nitride–titanium nitride (Si3N4–TiN) composite,” Journal of
Materials Science, vol. 52, no. 1, pp. 467–477, 2017.
[29] H. Masuda, C. Miller, H. P. Koeffler, H. Battifora, and M. J.
Cline, “Rearrangement of the p53 gene in human osteogenic
sarcomas,” Proceedings of the National Academy of Sciences,
vol. 84, no. 21, pp. 7716–7719, 1987.
[30] E. Murray, D. Provvedini, D. Curran, B. Catherwood,
H. Sussman, and S. Manolagas, “Characterization of a human
osteoblastic osteosarcoma cell line (SAOS-2) with high bone
alkaline phosphatase activity,” Journal of Bone and Mineral
Research, vol. 2, no. 3, pp. 231–238, 1978.
[31] H. Heremans, A. Billiau, J. J. Cassiman, J. C. Mulier, and P. De
Somer, “In vitro cultivation of human tumor tissues II.
Morphological and virological characterization of three cell
lines,” Oncologia, vol. 35, no. 6, pp. 246–252, 1978.
[32] R. J. Fernandes, M. A. Harkey, M. Weis, J. W. Askew, and
D. R. Eyre, “The post-translational phenotype of collagen
synthesized by SAOS-2 osteosarcoma cells,” Bone, vol. 40,
no. 5, pp. 1343–1351, 2007.
[33] L. G. Rao, M. K. Sutherland, G. S. Reddy, M. L. Siu-Caldera,
M.R.Uskokovic, andT.M.Murray, “Effects of 1alpha, 25-dihy-
droxy-16ene, 23yne-vitamin D3 on osteoblastic function in
humanosteosarcomaSaOS-2 cells: differentiation-stage depen-
dence andmodulation by 17-beta estradiol,”Bone, vol. 19, no. 5,
pp. 621–627,1996, January2017,http://www.ncbi.nlm.nih.gov/
pubmed/8968029.
[34] J. Clover, R. A. Dodds, and M. Gowen, “Integrin subunit
expression by human osteoblasts and osteoclasts in situ
and in culture,” Journal of Cell Science, vol. 103, Part 1,
1992.
[35] R. Olivares-Navarrete, P. Raz, G. Zhao et al., “Integrin
alpha2beta1 plays a critical role in osteoblast response to
micron-scale surface structure and surface energy of
titanium substrates,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 105,
no. 41, pp. 15767–15772, 2008.
[36] A. Kumarasuriyar, S. Murali, V. Nurcombe, and S. M. Cool,
“Glycosaminoglycan composition changes with MG-63 osteo-
sarcoma osteogenesis in vitro and induces human mesenchy-
mal stem cell aggregation,” Journal of Cellular Physiology,
vol. 218, no. 3, pp. 501–511, 2009.
[37] L. Saldaña, F. Bensiamar, A. Boré, and N. Vilaboa, “In search
of representative models of human bone-forming cells for
cytocompatibility studies,” Acta Biomaterialia, vol. 7, no. 12,
pp. 4210–4221, 2011.
[38] P. A. Zuk, M. Zhu, P. Ashjian et al., “Human adipose tissue is a
source of multipotent stem cells,”Molecular Biology of the Cell,
vol. 13, no. 12, pp. 4279–4295, 2002.
[39] “Stem Cells From Fat Focus Of International Fat Applied
Technology Society,” in Second Annual Meeting of the Interna-
tional Fat Applied Technology Society, Pittsburgh, PA, 2004.
[40] S. Lendeckel, A. Jödicke, P. Christophis et al., “Autologous
stem cells (adipose) and fibrin glue used to treat widespread
traumatic calvarial defects: case report,” Journal of Cranio-
Maxillo-Facial Surgery, vol. 32, no. 6, pp. 370–373, 2004.
[41] T. Thesleff, K. Lehtimäki, T. Niskakangas et al., “Cranioplasty
with adipose-derived stem cells and biomaterial: a novel
method for cranial reconstruction,” Neurosurgery, vol. 68,
no. 6, pp. 1535–1540, 2011.
[42] K. Mesimäki, B. Lindroos, J. Törnwall et al., “Novel maxillary
reconstruction with ectopic bone formation by GMP adipose
stem cells,” International Journal of Oral and Maxillofacial
Surgery, vol. 38, no. 3, pp. 201–209, 2009.
[43] A. Miranville, C. Heeschen, C. Sengenès, C. A. Curat, R. Busse,
and A. Bouloumié, “Improvement of postnatal neovasculariza-
tion by human adipose tissue-derived stem cells,” Circulation,
vol. 110, no. 3, pp. 349–355, 2004.
[44] V. Planat-Benard, J.-S. Silvestre, B. Cousin et al., “Plasticity of
human adipose lineage cells toward endothelial cells: physio-
logical and therapeutic perspectives,” Circulation, vol. 109,
no. 5, pp. 656–663, 2004.
[45] J. Rehman, D. Traktuev, J. Li et al., “Secretion of angiogenic
and antiapoptotic factors by human adipose stromal cells,”
Circulation, vol. 109, no. 10, pp. 1292–1298, 2004.
[46] G. E. Kilroy, S. J. Foster, X. Wu et al., “Cytokine profile of
human adipose-derived stem cells: expression of angiogenic,
hematopoietic, and pro-inflammatory factors,” Journal of
Cellular Physiology, vol. 212, no. 3, pp. 702–709, 2007.
[47] C. A. Ribeiro, J. S. Fraga, M. Grãos et al., “The secretome of
stem cells isolated from the adipose tissue and Wharton jelly
acts differently on central nervous system derived cell popula-
tions,” Stem Cell Research & Therapy, vol. 3, no. 3, p. 18, 2012.
[48] P. Succar, E. J. Breen, D. Kuah, and B. R. Herbert, “Alter-
ations in the secretome of clinically relevant preparations
of adipose-derived mesenchymal stem cells cocultured with
hyaluronan,” Stem Cells International, vol. 2015, Article ID
421253, p. 16, 2015.
[49] H. Kupcova Skalnikova, “Proteomic techniques for character-
isation of mesenchymal stem cell secretome,” Biochimie,
vol. 95, no. 12, pp. 2196–2211, 2013.
[50] D. T. Graves, Y. Jiang, and A. J. Valente, “The expression of
monocyte chemoattractant protein-1 and other chemokines
by osteoblasts,” Frontiers in Bioscience, vol. 4, pp. D571–
D580, 1999, August 2016, http://www.ncbi.nlm.nih.gov/
pubmed/10393126.
[51] P. Proost, C. De Wolf-Peeters, R. Conings, G. Opdenakker,
A. Billiau, and J. Van Damme, “Identification of a novel
granulocyte chemotactic protein (GCP-2) from human tumor
cells. In vitro and in vivo comparison with natural forms of
GRO, IP-10, and IL-8,” Journal of Immunology, vol. 150,
no. 3, pp. 1000–1010, 1993.
[52] T. Sobue, T. Gravely, A. Hand et al., “Regulation of fibroblast
growth factor 2 and fibroblast growth factor receptors by
transforming growth factor β in human osteoblastic MG-63
cells,” Journal of Bone and Mineral Research, vol. 17, no. 3,
pp. 502–512, 2002.
[53] S.-H. Shim, J. H. Hah, S.-Y. Hwang, D. S. Heo, and
M.-W. Sung, “Dexamethasone treatment inhibits VEGF
production via suppression of STAT3 in a head and neck
10 Stem Cells International
cancer cell line,” Oncology Reports, vol. 23, no. 4, pp. 1139–
1143, 2010, August 2016, http://www.ncbi.nlm.nih.gov/
pubmed/20204302.
[54] J. J. Logie, S. Ali, K. M. Marshall, M. M. S. Heck, B. R. Walker,
and P. W. F. Hadoke, “Glucocorticoid-mediated inhibition of
angiogenic changes in human endothelial cells is not caused
by reductions in cell proliferation or migration,” PloS One,
vol. 5, no. 12, article e14476, 2010.
[55] K. Hu and B. R. Olsen, “Osteoblast-derived VEGF regulates
osteoblast differentiation and bone formation during bone
repair,” The Journal of Clinical Investigation, vol. 126, no. 2,
pp. 509–526, 2016.
[56] Y.-Q. Yang, Y.-Y. Tan, R. Wong, A. Wenden, L.-K. Zhang, and
A. B. M. Rabie, “The role of vascular endothelial growth factor
in ossification,” International Journal of Oral Science, vol. 4,
no. 2, pp. 64–68, 2012.
[57] M. Ishikawa, H. Ito, T. Kitaori et al., “MCP/CCR2 signaling is
essential for recruitment of mesenchymal progenitor cells
during the early phase of fracture healing,” PloS One, vol. 9,
no. 8, article e104954, 2014.
[58] X. Li, L. Qin, M. Bergenstock, L. M. Bevelock, D. V. Novack,
and N. C. Partridge, “Parathyroid hormone stimulates
osteoblastic expression of MCP-1 to recruit and increase the
fusion of pre/osteoclasts,” The Journal of Biological Chemistry,
vol. 282, no. 45, pp. 33098–33106, 2007.
[59] A. Bajek, N. Gurtowska, J. Olkowska, L. Kazmierski, M. Maj,
and T. Drewa, “Adipose-derived stem cells as a tool in cell-
based therapies,” Archivum Immunologiae et Therapiae
Experimentalis (Warsz), vol. 64, no. 6, pp. 443–454, 2016.
[60] B. Péault, G. Asatrian, D. Pham, W. R. Hardy, and A. W.
James, “Stem cell technology for bone regeneration: current
status and potential applications,” Stem Cells and Cloning:
Advances and Applications, vol. 8, p. 39, 2015.
[61] G. K. Sándor, V. J. Tuovinen, J. Wolff et al., “Adipose stem cell
tissue–engineered construct used to treat large anterior
mandibular defect: a case report and review of the clinical
application of goodmanufacturing practice–level adipose stem
cells for bone regeneration,” Journal of Oral and Maxillofacial
Surgery, vol. 71, no. 5, pp. 938–950, 2013.
[62] M. Barba, C. Cicione, C. Bernardini, F. Michetti, and
W. Lattanzi, “Adipose-derived mesenchymal cells for bone
regereneration: state of the art,” BioMed Research Interna-
tional, vol. 2013, Article ID 416391, p. 11, 2013.
[63] B. E. Grottkau and Y. Lin, “Osteogenesis of adipose-derived
stem cells,” Bone Research, vol. 1, no. 2, pp. 133–145, 2013.
11Stem Cells International
Submit your manuscripts at
https://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Anatomy 
Research International
Peptides
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation 
http://www.hindawi.com
 International Journal of
Volume 201?
???????
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Molecular Biology 
International 
Genomics
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Bioinformatics
Advances in
Marine Biology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Signal Transduction
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Evolutionary Biology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Biochemistry 
Research International
Archaea
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Genetics 
Research International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Advances in
Virolog y
Hindawi Publishing Corporation
http://www.hindawi.com
Nucleic Acids
Journal of
Volume 2014
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Enzyme 
Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
International Journal of
Microbiology
